Cantor Fitzgerald Cuts MiMedx Group (NASDAQ:MDXG) Price Target to $8.00

MiMedx Group (NASDAQ:MDXG) had its price objective decreased by Cantor Fitzgerald from $12.00 to $8.00 in a research report sent to investors on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock.

Other research analysts have also issued reports about the company. Lake Street Capital lowered their price objective on MiMedx Group from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, January 20th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MiMedx Group in a research note on Monday, December 29th. Wall Street Zen raised MiMedx Group from a “buy” rating to a “strong-buy” rating in a research report on Sunday, November 2nd. Finally, Mizuho reduced their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Wednesday, December 17th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, MiMedx Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.33.

MiMedx Group Trading Down 0.4%

Shares of MDXG stock opened at $5.20 on Tuesday. The company has a current ratio of 4.41, a quick ratio of 3.95 and a debt-to-equity ratio of 0.07. MiMedx Group has a twelve month low of $4.89 and a twelve month high of $8.46. The company’s 50-day moving average price is $5.94 and its 200-day moving average price is $6.66. The stock has a market cap of $770.12 million, a price-to-earnings ratio of 19.26 and a beta of 1.59.

Hedge Funds Weigh In On MiMedx Group

Institutional investors have recently bought and sold shares of the company. First Light Asset Management LLC grew its holdings in shares of MiMedx Group by 89.5% in the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock valued at $25,498,000 after purchasing an additional 1,725,458 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in MiMedx Group in the 3rd quarter valued at approximately $10,237,000. Marshall Wace LLP boosted its position in MiMedx Group by 864.9% in the 4th quarter. Marshall Wace LLP now owns 1,381,288 shares of the company’s stock valued at $9,351,000 after buying an additional 1,238,132 shares during the period. Hillsdale Investment Management Inc. acquired a new position in shares of MiMedx Group in the fourth quarter worth $7,134,000. Finally, Disciplined Growth Investors Inc. MN increased its position in shares of MiMedx Group by 283.0% during the third quarter. Disciplined Growth Investors Inc. MN now owns 1,383,451 shares of the company’s stock worth $9,656,000 after acquiring an additional 1,022,202 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.